Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 7
Submit an article Journal homepage
235
Views
20
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial

Asher Chanan-Khan Department of Medicine; Department of Molecular Targets and Experimental TherapeuticsCorrespondence[email protected]
,
Kena C. Miller Department of Medicine
,
Laurie Musial Department of Clinical Research Services
,
Swaminathan Padmanabhan Department of Medicine
,
Jihnhee Yu Department of Biostatistics
,
Sikander Ailawadhi Department of Medicine
,
Taimur Sher Department of Medicine
,
Alice Mohr Department of Medicine
,
Zale P. Bernstein Department of Medicine
,
Maurice Barcos Department of Pathology and Immunology
,
Mehul Patel Department of Medicine
,
Dan Iancu Department of Pathology and Immunology
,
Kelvin Lee Department of Medicine; Department of Immunology, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
&
Myron S. Czuczman Department of Medicine
 show all
Pages 1096-1101 | Received 30 Oct 2008, Accepted 17 Mar 2009, Published online: 21 Jul 2009

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Jacob P Laubach, Peter M Voorhees, Hani Hassoun, Andrzej Jakubowiak, Sagar Lonial & Paul G Richardson. (2014) Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Review of Hematology 7:1, pages 97-111.
Read now
Michel Delforge. (2011) Bortezomib for previously untreated multiple myeloma. Expert Opinion on Pharmacotherapy 12:16, pages 2553-2564.
Read now
Rachid Baz, Mehul Patel, Elizabeth Finley-Oliver, Daniel Lebovic, Mohamad A. Hussein, Kena C. Miller, Margaret Wood, Taimur Sher, Kelvin Lee & Asher A. Chanan-Khan. (2010) Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leukemia & Lymphoma 51:6, pages 1015-1019.
Read now

Articles from other publishers (17)

Cyrille Hulin, Javier de la Rubia, Meletios A. Dimopoulos, Evangelos Terpos, Eirini Katodritou, Vania Hungria, Hadewijch De Samblanx, Anne-Marie Stoppa, Jesper Aagesen, Deniz Sargin, Anastasia Sioni, Andrew Belch, Joris Diels, Robert A. Olie, Don RobinsonJrJr, Anna Potamianou, Helgi van de Velde & Michel Delforge. (2019) Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. Health Science Reports 2:1, pages e104.
Crossref
Chi Zhang, Ken Dower, Baohong Zhang, Robert V. Martinez, Lih-Ling Lin & Shanrong Zhao. (2018) Computational identification and validation of alternative splicing in ZSF1 rat RNA-seq data, a preclinical model for type 2 diabetic nephropathy. Scientific Reports 8:1.
Crossref
Shang-Yi Huang, Cheng-Shyong Chang, Ta-Chih Liu, Po-Nan Wang, Su-Peng Yeh, Ching-Liang Ho, Ming-Chung Kuo, Hsuan-Yu Lin, Jan de Jong, Jia-Yi Chen & Ya-Wen Yang. (2018) Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma. Hematological Oncology 36:1, pages 238-244.
Crossref
Carl James May, Moin Saleem & Gavin Iain Welsh. (2014) Podocyte Dedifferentiation: A Specialized Process for a Specialized Cell. Frontiers in Endocrinology 5.
Crossref
Yongqing Zhang, Hongjuan Liu, Xiequn Chen, Qingxian Bai, Rong Liang, Bing Shi, Lihui Liu, DengMei Tian & Mingjuan Liu. (2014) Modified Bortezomib, Adriamycin and Dexamethasone (PAD) Regimen in Advanced Multiple Myeloma. Pathology & Oncology Research 20:4, pages 987-995.
Crossref
Matthew J. Streetly, Jacob Laubach, Paul Richardson & Stephen A. Schey. 2013. Myeloma. Myeloma 144 166 .
Maria T. Petrucci, Pilar Giraldo, Paolo Corradini, Adriana Teixeira, Meletios A. Dimopoulos, Igor W. Blau, Johannes Drach, Ralf Angermund, Nathalie Allietta, Esther Broer, Vivien Mitchell & Joan Bladé. (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British Journal of Haematology 160:5, pages 649-659.
Crossref
Omar S Aljitawi & Joseph P McGuirk. (2012) Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what’s new?. Journal of Comparative Effectiveness Research 1:1, pages 57-70.
Crossref
Laura A.A. GilliamDaret K. St. Clair. (2011) Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress. Antioxidants & Redox Signaling 15:9, pages 2543-2563.
Crossref
Beth M. Faiman, Patricia Mangan, Jacy Spong & Joseph D. Tariman. (2011) Renal Complications in Multiple Myeloma and Related Disorders. Clinical Journal of Oncology Nursing 15:0, pages 66-76.
Crossref
Taimur Sher, Sikander Ailawadhi, Kena C. Miller, Debbie Manfredi, Margaret Wood, Wei Tan, Gregory Wilding, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri, Fredrick Hong, Raman Sood, Saif Soniwala, William Lawrence, Saad Jamshed, Aisha Masood, Daniel Iancu, Kelvin Lee & Asher Chanan-Khan. (2011) A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British Journal of Haematology 154:1, pages 104-110.
Crossref
Niels W.C.J. van de Donk, Henk M. Lokhorst, Meletios Dimopoulos, Michele Cavo, Gareth Morgan, Hermann Einsele, Martin Kropff, Steve Schey, Hervé Avet-Loiseau, Heinz Ludwig, Hartmut Goldschmidt, Pieter Sonneveld, Hans E. Johnsen, Joan Bladé, Jesús F. San-Miguel & Antonio Palumbo. (2011) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews 37:4, pages 266-283.
Crossref
Jatin J. Shah & Robert Z. Orlowski. 2011. Bortezomib in the Treatment of Multiple Myeloma. Bortezomib in the Treatment of Multiple Myeloma 79 94 .
Nina ShahSagar Lonial. (2010) Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. Hematology 2010:1, pages 310-313.
Crossref
Tiffany Richards & Donna Weber. (2010) Advances in treatment for relapses and refractory multiple myeloma. Medical Oncology 27:S1, pages 25-42.
Crossref
Sheeba K. Thomas, Tiffany A. Richards & Donna M. Weber. (2009) Novel Agents for Relapsed and/or Refractory Multiple Myeloma. The Cancer Journal 15:6, pages 485-493.
Crossref
Morie Gertz. (2009) Finishing off fibrils. Blood 114:8, pages 1456-1457.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.